View Older Stories View More Recent Stories
-
ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
-
NVO INVESTOR DEADLINE: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK620 at Bernstein SocGen Group
-
Morgan Stanley Starts Novo Nordisk (NOVOB:DC) (NVO) at Equalweight
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
NVO CLASS ACTION UPDATE: Novo Nordisk Investors are Reminded to Contact BFA Law before Imminent March 25 Deadline
-
Bernstein explains why this Big Pharma stock should 'continue to work'
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
-
Novo Nordisk (NVO) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by March 25 Deadline
-
Bernstein explains why this big pharma stock continue to work
-
NVO INVESTOR DEADLINE: Novo Nordisk Investors are Alerted to Contact BFA Law before the Imminent March 25 Class Action Deadline
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK1,000 at JPMorgan
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
NVO CLASS ACTION: BFA Law Alerts Novo Nordisk Investors of the Imminent March 25 Class Action Deadline
-
Novo Nordisk (NVO) Reports Q4 EPS of DKK6.34; offers outlook
-
Novo Nordisk earnings preview: BofA analysts weigh in ahead of Q4 results
-
NVO INVESTOR ALERT: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
Novo Nordisk (NVO) call put ratio 1.7 calls to 1 put into quarter results
-
Novo Nordisk (NVO) call put ratio 1.5 calls to 1 put into quarter results
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
-
NVO INVESTOR NOTICE: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
Eli Lilly & Co. (LLY), Novo (NVO) see mid-day upside
-
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) following latest Ozempic approval
-
FDA approves Novo Nordisk's (NVO) Ozempic as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD
-
Novo Nordisk (NVO) sees pre-open selling pressure
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) Amid Solid SubQ Amycretin Results
-
Novo Nordisk (NVO) successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
-
Novo Nordisk (NVO) call put ratio 1 call to 1 put into share price up before the bell
-
Novo Nordisk (NVO) call put ratio 2.5 calls to 1 put
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) PT Lowered to $90 at CFRA
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo's (NVO) Ozempic, Wegovy Targeted In Medicare Price Negotiations - Bloomberg
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK798 at Guggenheim

